By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.
The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.
In the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.
Ongoing education and proven outcomes need to aid this form of testing.
This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.
Imprecise language can fuel infodemics and misinformation and damage public trust.
Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).
Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.
In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.
The recombinant human IgG1κ monoclonal antibody binds and neutralizes the virus.
Here is a review of using this therapy in this patient population.
The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.
Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.
Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.
Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.
This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.
Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?
Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.
The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.
A cautious approach for now is warranted as well as a need for a randomized clinical trial.
For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.
With potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.
This novel, rapid diagnostic assay uses polymerase chain reaction and magnetic resonance to identify the 5 most common Candida species.
Access to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.
Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
This flu season, the CDC reported at least 2.4 million flu illnesses, 23,000 hospitalizations, and 1,400 deaths from flu so far.